Clinical Study on the Treatment of Stable Bronchiectasis With Bailing Capsules Combined With Guben Kechuan Granules

Status: Recruiting
Location: See all (5) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

The goal of this clinical trial is to learn if Bailing Capsules in combination Guben Kechuan Granules works to treat stable bronchiectasis in adults.It will also learn about the safety of Bailing Capsules in combination Guben Kechuan Granules The main questions it aims to answer are: Does Bailing Capsules in combination Guben Kechuan Granules lower the number of acute exacerbation in patients with stable bronchiectasis? The safety of the combination of Bailing Capsules and Guben Kechuan Granules ? Researchers will compare the combination of Bailing Capsules and Guben Kechuan Granules to standard Western medical treatment to see if them works to treat stable bronchiectasis. Participants will: Take Bailing Capsules orally (four capsules each time, three times a day) and Guben Kechuan Granules ( three times a day, 1 bag each time )on the basis of standard Western medical treatment or only standard Western medical treatment for 24 weeks Visit the clinic for checkups and tests on 4, 12, 24, 48 weeks Keep a diary of their symptoms

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:

• 18-80 years old, gender not limited;

• It conforms to the Western medical diagnosis of bronchiectasis;

• There has been no acute exacerbation or respiratory tract infection in the past 4 weeks. (Acute exacerbation is defined as the deterioration of three or more of the following six conditions: cough, changes in sputum volume, purulent sputum, breathing difficulties or exercise tolerance, fatigue or discomfort, and hemoptysis, lasting for more than 48 hours, and considered by the clinician to require treatment);

• There have been at least two documented acute exacerbations in the past year, prescribed by doctors and diagnosed as signs and symptoms of respiratory tract infections;

• Pulmonary function tests can be conducted, and there is evidence of airflow limitation when screening vital capacity (FEV1/FVC ratio \<70%, and clinically stable at the time of entering the study);

• Voluntarily participate in this clinical trial and sign the informed consent form.

Locations
Other Locations
China
The Second Affiliated Hospital, Zhejiang University School of Medicine
RECRUITING
Hangzhou
Huzhou Central Hospital
NOT_YET_RECRUITING
Huzhou
Jinhua Central Hospital
NOT_YET_RECRUITING
Jinhua
Yueqing People's Hospital
NOT_YET_RECRUITING
Yueqing
Zhoushan Hospital
NOT_YET_RECRUITING
Zhoushan
Contact Information
Primary
Haibin Dai
haibindai@163.com
(0571)87783759
Time Frame
Start Date: 2025-07-14
Estimated Completion Date: 2027-12-30
Participants
Target number of participants: 214
Treatments
Experimental: Experimental group
Bailing Capsules orally (four capsules each time, three times a day) and Guben Kechuan Granules (1 bag each time, three times a day) on the basis of standard Western medical treatment
No_intervention: Control group
standard Western medical treatment
Sponsors
Collaborators: Jinhua Central Hospital, ZhuZhou Central Hospital, Affiliated Yueqing Hospital of Wenzhou Medical University, Shanghai Zhongshan Hospital
Leads: Second Affiliated Hospital, School of Medicine, Zhejiang University

This content was sourced from clinicaltrials.gov